Introduction to a review series on acute lymphoblastic leukemia

Abstract

Our understanding of the biology of acute lymphoblastic leukemia (ALL) continues to be refined, and these advances naturally lead to improvements in therapy and outcomes for pediatric and adult patients. Associate Editor Hervé Dombret introduces this series of reviews that bring readers up to date with the biology of both B-cell and T-cell ALL (B-ALL and T-ALL) as well as the latest approaches to first-line therapy. Passet et al discuss the different genetic subtypes of B-ALL and their implications, while Pölönen and colleagues discuss T-ALL, highlighting how biology informs classification and in turn prognostication and therapy. Badar and coauthors explore how the incorporation of immunotherapy is revolutionizing treatment regimens. Finally, Rampotas and Roddie focus specifically on the role of chimeric antigen receptor T cells in management of patients with B-ALL now and in the future.